Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Conavi Medical ( (TSE:CNVI) ) has issued an announcement.
Conavi Medical’s Novasight Hybrid™ System has been awarded ‘Product Innovation of the Year’ at the 2025 Minnesota Manufacturing Awards, recognizing its groundbreaking advancement in intracoronary imaging technology. This accolade highlights the system’s unique ability to provide comprehensive insights during complex coronary procedures, enhancing decision-making for optimal patient outcomes. The award underscores Conavi Medical’s innovative positioning in the medical device industry and its collaboration with Minnetronix Medical, as the company prepares for the commercial launch of its next-generation Novasight.
More about Conavi Medical
Conavi Medical is a medical device company that specializes in designing, manufacturing, and marketing imaging technologies to assist in minimally invasive cardiovascular procedures. Their flagship product, the Novasight Hybrid™ System, is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous imaging of coronary arteries, with regulatory approvals in the U.S., Canada, China, and Japan.
Average Trading Volume: 37,405
Technical Sentiment Signal: Sell
Current Market Cap: C$6.81M
Find detailed analytics on CNVI stock on TipRanks’ Stock Analysis page.